nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

11.10.2023 | Original Article

Total-body PET/CT with half-dose [⁶⁸ Ga]Ga-PSMA-11 for biochemical recurrent prostate cancer: comparable diagnostic value to short axial field-of-view PET/CT with full-dose [⁶⁸ Ga]Ga-PSMA-11

verfasst von: Yuheng Liu, Lianghua Li, Yanyu Qin, Zijun Chen, Haitao Zhao, Xinlu Wang, Ruohua Chen

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The objective of this study was to evaluate the diagnostic performance and image quality of total-body positron emission tomography/computed tomography (PET/CT) imaging using a half-dose of [⁶⁸ Ga]Ga-prostate specific membrane antigen ([⁶⁸ Ga]Ga-PSMA) radiotracer, compared to conventional short axial field-of-view PET/CT imaging using a full dose of [⁶⁸ Ga]Ga-PSMA.

Methods

This retrospective study enrolled 52 patients with biochemical recurrent (BCR) prostate cancer after radical prostatectomy who underwent total-body PET/CT with a half-dose (0.9–1.1 MBq/kg) of [⁶⁸ Ga]Ga-PSMA. These patients were matched by baseline characteristics to another 52 BCR patients after prostatectomy who underwent conventional PET/CT with a full dose (1.8–2.2 MBq/kg) of [⁶⁸ Ga]Ga-PSMA. The half-dose group was further divided into 5-min (G5) and 2-min (G2) acquisition subgroups. Image quality was assessed through subjective analysis using a 5-point scale and objective measurements of standard uptake value maximum (SUVmax), standard uptake value mean (SUVmean), background variation (BV) of the liver, blood pool, and parotid glands. Additionally, SUVmax and tumor-to-background ratio (TBR) were calculated for lesions.

Results

No significant difference in subjective image quality was found between the G2 and full-dose groups (p > 0.05). PET/CT image quality was significantly higher for the G5 versus G2 (p < 0.001) and full-dose groups (p < 0.001). TBR did not differ between the G2 and full-dose groups (4.23 ± 5.21 vs 4.22 ± 3.97, p = 0.99). Liver BV was significantly lower for G2 versus full-dose groups (0.16 ± 0.03 vs 0.20 ± 0.05, p < 0.001).

Conclusions

Total-body PET/CT with a half-dose [⁶⁸ Ga]Ga-PSMA yields image quality superior or comparable to that of conventional PET/CT. The utilization of total-body [⁶⁸ Ga]Ga-PSMA PET/CT meets the diagnostic demands of BCR patients, particularly those who exhibit reduced tolerance to prolonged horizontal positioning and scan durations, while simultaneously reducing radiation exposure for the subjects.

Schatten H. Brief overview of prostate cancer statistics, grading, diagnosis and treatment strategies. Adv Exp Med Biol. 2018;1095:1–14. https://doi.org/10.1007/978-3-319-95693-0_1.CrossRef

Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends–an update. Cancer Epidemiol Biomark Prev. 2016;25:16–27. https://doi.org/10.1158/1055-9965.Epi-15-0578.CrossRef

Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol. 2016;13:226–35. https://doi.org/10.1038/nrurol.2016.26.CrossRefPubMed

Tsechelidis I, Vrachimis A. PSMA PET in imaging prostate cancer. Front Oncol. 2022;12: 831429. https://doi.org/10.3389/fonc.2022.831429.CrossRefPubMedPubMedCentral

Ng QK, Triumbari EKA, Omidvari N, Cherry SR, Badawi RD, Nardo L. Total-body PET/CT - first clinical experiences and future perspectives. Semin Nucl Med. 2022;52:330–9. https://doi.org/10.1053/j.semnuclmed.2022.01.002.CrossRefPubMedPubMedCentral

Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. (68)Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44:1014–24. https://doi.org/10.1007/s00259-017-3670-z.CrossRefPubMed

Nadig V, Herrmann K, Mottaghy FM, Schulz V. Hybrid total-body pet scanners-current status and future perspectives. Eur J Nucl Med Mol Imaging. 2022;49:445–59. https://doi.org/10.1007/s00259-021-05536-4.CrossRef

Lan X, Fan K, Li K, Cai W. Dynamic PET imaging with ultra-low-activity of (18)F-FDG: unleashing the potential of total-body PET. Eur J Nucl Med Mol Imaging. 2021;48:4138–41. https://doi.org/10.1007/s00259-021-05214-5.CrossRefPubMedCentral

Spencer BA, Berg E, Schmall JP, Omidvari N, Leung EK, Abdelhafez YG, et al. Performance evaluation of the uEXPLORER total-body PET/CT scanner based on NEMA NU 2–2018 with additional tests to characterize PET scanners with a long axial field of view. J Nucl Med. 2021;62:861–70. https://doi.org/10.2967/jnumed.120.250597.CrossRefPubMedPubMedCentral

10.

Chen W, Liu L, Li Y, Li S, Li Z, Zhang W, et al. Evaluation of pediatric malignancies using total-body PET/CT with half-dose [(18)F]-FDG. Eur J Nucl Med Mol Imaging. 2022;49:4145–55. https://doi.org/10.1007/s00259-022-05893-8.CrossRefPubMed

11.

Tan H, Sui X, Yin H, Yu H, Gu Y, Chen S, et al. Total-body PET/CT using half-dose FDG and compared with conventional PET/CT using full-dose FDG in lung cancer. Eur J Nucl Med Mol Imaging. 2021;48:1966–75. https://doi.org/10.1007/s00259-020-05091-4.CrossRefPubMed

12.

Demirci E, Sahin OE, Ocak M, Akovali B, Nematyazar J, Kabasakal L. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging. Nucl Med Commun. 2016;37:1169–79. https://doi.org/10.1097/MNM.0000000000000566.CrossRefPubMed

13.

Ceci F, Oprea-Lager DE, Emmett L, Adam JA, Bomanji J, Czernin J, et al. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging. 2021;48:1626–38. https://doi.org/10.1007/s00259-021-05245-y.CrossRefPubMedPubMedCentral

14.

Cerci JJ, Fanti S, Lobato EE, Kunikowska J, Alonso O, Medina S, et al. Diagnostic performance and clinical impact of (68)Ga-PSMA-11 PET/CT imaging in early relapsed prostate cancer after radical therapy: a prospective multicenter study (IAEA-PSMA Study). J Nucl Med. 2022;63:240–7. https://doi.org/10.2967/jnumed.120.261886.CrossRefPubMedPubMedCentral

15.

Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, et al. Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017;44:1258–68. https://doi.org/10.1007/s00259-017-3711-7.CrossRefPubMedPubMedCentral

16.

Ekmekcioglu Ö, Busstra M, Klass ND, Verzijlbergen F. Bridging the imaging gap: PSMA PET/CT has a high impact on treatment planning in prostate cancer patients with biochemical recurrence-a narrative review of the literature. J Nucl Med. 2019;60:1394–8. https://doi.org/10.2967/jnumed.118.222885.CrossRefPubMed

17.

Halpern BS, Dahlbom M, Quon A, Schiepers C, Waldherr C, Silverman DH, et al. Impact of patient weight and emission scan duration on PET/CT image quality and lesion detectability. J Nucl Med. 2004;45:797–801.

18.

Hausmann D, Dinter DJ, Sadick M, Brade J, Schoenberg SO, Büsing K. The impact of acquisition time on image quality in whole-body 18F-FDG PET/CT for cancer staging. J Nucl Med Technol. 2012;40:255–8. https://doi.org/10.2967/jnmt.112.103291.CrossRefPubMed

19.

Akamatsu G, Ishikawa K, Mitsumoto K, Taniguchi T, Ohya N, Baba S, et al. Improvement in PET/CT image quality with a combination of point-spread function and time-of-flight in relation to reconstruction parameters. J Nucl Med. 2012;53:1716–22. https://doi.org/10.2967/jnumed.112.103861.CrossRefPubMed

20.

Hu Y, Liu G, Yu H, Wang Y, Li C, Tan H, et al. Feasibility of acquisitions using total-body PET/CT with an ultra-low (18)F-FDG activity. J Nucl Med. 2022;63:959–65. https://doi.org/10.2967/jnumed.121.262038.CrossRefPubMedPubMedCentral

21.

Abdelhafez Y, Raychaudhuri SP, Mazza D, Sarkar S, Hunt HL, McBride K, et al. Total-Body (18)F-FDG PET/CT in autoimmune inflammatory arthritis at ultra-low dose: initial observations. J Nucl Med. 2022;63:1579–85. https://doi.org/10.2967/jnumed.121.263774.CrossRefPubMedPubMedCentral

Titel: Total-body PET/CT with half-dose [68 Ga]Ga-PSMA-11 for biochemical recurrent prostate cancer: comparable diagnostic value to short axial field-of-view PET/CT with full-dose [68 Ga]Ga-PSMA-11
verfasst von: Yuheng Liu
Lianghua Li
Yanyu Qin
Zijun Chen
Haitao Zhao
Xinlu Wang
Ruohua Chen
Publikationsdatum: 11.10.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 2/2024
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-023-06466-z

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Total-body PET/CT with half-dose [⁶⁸ Ga]Ga-PSMA-11 for biochemical recurrent prostate cancer: comparable diagnostic value to short axial field-of-view PET/CT with full-dose [⁶⁸ Ga]Ga-PSMA-11

Abstract

Purpose

Methods

Results

Conclusions

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2024

Sentinel lymph node detection in thyroid carcinoma using [68Ga]Ga-tilmanocept PET/CT: a proof-of-concept study

Letter to the editor concerning “Reproducibility of [18F]FDG PET/CT liver SUV as reference or normalisation factor”

Diagnostic accuracy of anti-3-[18F]-FACBC PET/MRI in gliomas

PET image denoising based on denoising diffusion probabilistic model

In vivo cerebral metabolic and dopaminergic characteristics in multiple system atrophy with orthostatic hypotension

International consensus on clinical use of presynaptic dopaminergic positron emission tomography imaging in parkinsonism